Literature DB >> 8314853

Induction of GTP-cyclohydrolase I mRNA expression by lectin activation and interferon-gamma treatment in human cells associated with the immune response.

K Schott1, M Gütlich, I Ziegler.   

Abstract

The development of tetrahydrobiopterin synthesis during lectin stimulation of resting human T lymphocytes (Kerler et al. [1989] FEBS Lett., 250:622-624), the interferon-gamma induced neopterin production by human monocytes/macrophages (Huber et al. [1984] J. Exp. Med., 160:310-316), and the control of tetrahydrobiopterin synthesis in activated T cells by the synergistic action of interferon-gamma and interleukin 2 (Ziegler et al. [1990] J. Biol. Chem. 265:17026-17030) were previously explained by modulation of the apparent GTP-cyclohydrolase I activation. In this study we demonstrate that increases in GTP-cyclohydrolase I activity which occur after lectin induction and after cytokine treatment correlate with increased steady state mRNA levels specific for this enzyme. The enhancement of interferon-gamma induced enzyme activity in primed T cells by interleukin 2 also corresponds to further increases in mRNA expression. The steady state GTP-cyclohydrolase I mRNA levels in primed T cells, however, do not correlate with the steep decline which follows the culmination of enzyme activity 44 hours after treatment. This indicates that the down-regulation of apparent GTP-cyclohydrolase I activity is caused by posttranslational modification of the protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314853     DOI: 10.1002/jcp.1041560103

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Molecular cloning of a cDNA coding for GTP cyclohydrolase I from Dictyostelium discoideum.

Authors:  K Witter; D J Cahill; T Werner; I Ziegler; W Rödl; A Bacher; M Gütlich
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

2.  Control of 6-(D-threo-1',2'-dihydroxypropyl) pterin (dictyopterin) synthesis during aggregation of Dictyostelium discoideum. Involvement of the G-protein-linked signalling pathway in the regulation of GTP cyclohydrolase I activity.

Authors:  M Gütlich; K Witter; J Bourdais; M Veron; W Rödl; I Ziegler
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

3.  Interleukin 1 beta and cAMP trigger the expression of GTP cyclohydrolase I in rat renal mesangial cells.

Authors:  C Plüss; E R Werner; N Blau; H Wachter; J Pfeilschifter
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

4.  Identification of abundant mRNAs from the third stage larvae of the parasitic nematode, ostertagia ostertagi.

Authors:  J Moore; L Tetley; E Devaney
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

5.  Human GTP cyclohydrolase I: only one out of three cDNA isoforms gives rise to the active enzyme.

Authors:  M Gütlich; E Jaeger; K P Rücknagel; T Werner; W Rödl; I Ziegler; A Bacher
Journal:  Biochem J       Date:  1994-08-15       Impact factor: 3.857

6.  The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.

Authors:  R Zeidler; J Mysliwietz; M Csánady; A Walz; I Ziegler; B Schmitt; B Wollenberg; H Lindhofer
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

7.  A machine-learned analysis of human gene polymorphisms modulating persisting pain points to major roles of neuroimmune processes.

Authors:  D Kringel; C Lippmann; M J Parnham; E Kalso; A Ultsch; J Lötsch
Journal:  Eur J Pain       Date:  2018-07-13       Impact factor: 3.931

8.  Computational Functional Genomics-Based AmpliSeq™ Panel for Next-Generation Sequencing of Key Genes of Pain.

Authors:  Dario Kringel; Sebastian Malkusch; Eija Kalso; Jörn Lötsch
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

9.  Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain.

Authors:  Dario Kringel; Mari A Kaunisto; Catharina Lippmann; Eija Kalso; Jörn Lötsch
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.